HK68793A - Biologically active lysine containing octapeptides - Google Patents

Biologically active lysine containing octapeptides Download PDF

Info

Publication number
HK68793A
HK68793A HK687/93A HK68793A HK68793A HK 68793 A HK68793 A HK 68793A HK 687/93 A HK687/93 A HK 687/93A HK 68793 A HK68793 A HK 68793A HK 68793 A HK68793 A HK 68793A
Authority
HK
Hong Kong
Prior art keywords
trp
sub
phe
thr
cys
Prior art date
Application number
HK687/93A
Other languages
English (en)
French (fr)
Inventor
Andrew V. Schally
Ren Zhl Cal
Original Assignee
The Administrators Of The Tulane University Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/727,105 external-priority patent/US4650787A/en
Application filed by The Administrators Of The Tulane University Educational Fund filed Critical The Administrators Of The Tulane University Educational Fund
Publication of HK68793A publication Critical patent/HK68793A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (9)

  1. Verbindung der Formel worin
    a) X L-Tyrosin (L-Tyr) und Y L-Valin (L-Val) darstellen; oder
    b) X L-Phenylalanin (L-Phe) und Y L-Threonin (L-Thr) darstellen; und
    A eine L, D oder DL Aminosaüre die aus der Gruppe bestehend aus Phenylalanin (Phe), para-Chlor-phenylalanin (p-Cl-Phe) und Tryptophan (Trp) oder deren acetylierte Derivaten ausgewählt wird; und B eine L, D oder DL Aminosaüre die aus der Gruppe bestehend aus Threoninamid (Thr-NH₂) und Tryptophanamid (Trp-NH₂) ausgewählt wird, und deren pharmazeutisch akzeptable Saüreadditionssalze; mit der Bedingung dass, B kann nicht D-Thr-NH₂ darstellen wenn A D-Phe, X L-Phe und L-Thr sind.
  2. Verbindung der Formel (I) nach Anspruch 1, worin A Phenylalanin (Phe) ist, B Threoninamid (Thr-NH₂) oder (Trp-NH₂) ist, X L-Tyrosin (L-Tyr) und Y L-Valin (L-Val) darstellen.
  3. Verbindung der Formel (I) nach Anspruch 1, worin A Phenylalanin (Phe), Acetylphenylalanin (Ac-Phe) oder Tryptophan (Trp) ist, B Threoninamid (Thr-NH₂) oder Tryptophanamid (Trp-NH₂) ist, X L-Phenylalanin (L-Phe) und Y L-Threonin (L-Thr) darstellen.
  4. Verbindung der Formel (I) nach Anspruch 1, ausgewählt aus der Gruppe bestehend aus
  5. Verfahren zur Herstellung eine Verbindung der Formel (I) nach Anspruch 1, dadurch gekennzeichnet, dass man eine Verbindung der formel         A - Cys - X - D-Trp - Lys - Y - Cys - B   (I') worin Symbole A, B, X und Y wie im Anspruch 1 definiert sind, oxidiert.
  6. Pharmazeutisches Präparat für die Behandlung von Krebsartigen Tumoren enthaltend, als aktiver Bestandteil, eine Verbindung der Formel (I) nach Anspruch 1, oder deren pharmazeutisch akzeptables Saüreadditionssalze, zusammen mit einem flüssigen oder festen pharmazeutisch akzeptablen Träger.
  7. Pharmazeutisches Präparat nach Anspruch 6 für die Behandlung von Prostatakarzinoma, Mammakarzinoma, Insulinoma, Gastrinoma, Chondrosarkoma, Osteosarkoma und Pankreaskarzinoma.
  8. Pharmaceutisches Präparat nach Anspruch 6 oder 7, dadurch gekennzeichnet, dass es den aktiven Mikrokapseln aus Poly (d, l-lactid-co-glycolid) enthält.
  9. Pharmazeutisches Präparat nach einem des Ansprüche 6 durch 8, dadurch gekennzeichnet, dass es als aktiver Bestandteil eine Verbindung der Formel (I) nach Anspruch 1 ausgewählt aus der Gruppe bestehend aus und deren pharmazeutisch akzeptable Saüreadditionssalze, enthält.
HK687/93A 1985-04-25 1993-07-15 Biologically active lysine containing octapeptides HK68793A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/727,105 US4650787A (en) 1985-04-25 1985-04-25 Biologically active octapeptides
US06/843,539 US4725577A (en) 1985-04-25 1986-03-28 Biologically active lysine containing octapeptides

Publications (1)

Publication Number Publication Date
HK68793A true HK68793A (en) 1993-07-23

Family

ID=27111452

Family Applications (1)

Application Number Title Priority Date Filing Date
HK687/93A HK68793A (en) 1985-04-25 1993-07-15 Biologically active lysine containing octapeptides

Country Status (10)

Country Link
US (1) US4725577A (de)
EP (1) EP0203031B1 (de)
AT (1) ATE78831T1 (de)
AU (1) AU600895B2 (de)
CA (1) CA1333646C (de)
DE (1) DE3686200T2 (de)
DK (1) DK174920B1 (de)
HK (1) HK68793A (de)
IE (1) IE59621B1 (de)
SG (1) SG57793G (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
GR862206B (en) * 1985-09-12 1986-12-31 Univ Tulane Therapeutic somatostatin analogs
JPH085913B2 (ja) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
DE3726517A1 (de) * 1986-08-18 1988-03-03 Sandoz Ag Nasale zusammensetzungen, welche octreotid enthalten
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
AU639371B2 (en) * 1987-07-10 1993-07-22 Novartis Ag Method of treating breast cancer
US5073541A (en) * 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
US5068221A (en) * 1989-05-09 1991-11-26 Mathias John R Treatment of motility disorders with a gnrh analog
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ES2091907T3 (es) * 1989-12-08 1996-11-16 Univ Tulane Analogos octapeptidos de somatostina con una threonina en la sexta posicion.
GB9004017D0 (en) * 1990-02-22 1990-04-18 Krenning Eric P Improvements in or relating to organic compounds
ATE124054T1 (de) * 1990-04-06 1995-07-15 Univ Tulane Somatostatinanaloge.
IT1240643B (it) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5668254A (en) * 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5872100A (en) * 1990-05-11 1999-02-16 Deghenghi; Romano Peptides containing D-2-Alkyl-Tryptophan
US5434136A (en) * 1990-12-14 1995-07-18 Mathias; John R. Treatment of motility disorders with a GNRH analog
HU207104B (en) * 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
WO1995000553A1 (en) 1993-06-23 1995-01-05 Diatech, Inc. Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
US5504069A (en) * 1993-02-11 1996-04-02 Biomeasure, Inc. Inhibition of trauma-induced tumor growth
FR2701952B1 (fr) * 1993-02-22 1995-03-31 Adir Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6051206A (en) * 1994-06-03 2000-04-18 Diatide, Inc Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
US6100377A (en) * 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
DE69528531T2 (de) * 1994-09-27 2003-06-05 Ardana Bioscience Ltd., Edinburgh D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US5770687A (en) * 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
JPH09328499A (ja) * 1996-02-20 1997-12-22 American Cyanamid Co 純粋なソマトスタチンアンタゴニストおよびその使用方法
US6262229B1 (en) 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
US5972895A (en) * 1996-12-11 1999-10-26 A. Glenn Braswell Composition and method for increasing growth hormone levels
DK0979098T3 (da) * 1997-05-01 2003-07-14 Sod Conseils Rech Applic Fremgangsmåde til behandling af hyperprolaktinæmi og prolaktinomer
EP1332762A1 (de) * 1997-05-01 2003-08-06 Cedars-Sinai Medical Center Methode zur Behandlung von Hyperprolaktinämia und Prolaktinomen
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
CA2289499C (en) * 1997-05-13 2010-02-23 Michael Anthony Cawthorne Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x
CA2290592A1 (en) * 1997-05-13 1998-11-19 Michael Anthony Cawthorne Somatostatin and somatostatin agonists for decreasing body weight
EP0981364B1 (de) * 1997-05-13 2006-03-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Methoden und zusammensetzungen zur behandlung der hyperlipidämie
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
NZ530007A (en) 2001-06-08 2006-02-24 Sod Conseils Rech Applic Somatostatin-dopamine chimeric analogues that retain both somatostatin and dopamine activity in vivo and display enhanced biological activity
CA2523197C (en) 2003-04-22 2016-05-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide vectors
US20070111930A1 (en) * 2005-11-10 2007-05-17 Palle Venkata Raghavendra A Process for preparing vapreotide
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
PL2383289T3 (pl) 2006-10-16 2015-03-31 Salk Inst Biological Studies Antagoniści somatostatyny selektywni względem receptora (SSTR2)
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
EP2310028B1 (de) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusionsproteine zur Verwendung bei der Behandlung von Akromegalie
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
EP3007704B1 (de) 2013-06-13 2021-01-06 Antisense Therapeutics Ltd Kombinationstherapie der akromegalie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209426A (en) * 1979-05-29 1980-06-24 American Home Products Corporation Polypeptides related to somatostatin
DE3062075D1 (en) * 1979-11-27 1983-03-24 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4282143A (en) * 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
DK81082A (da) * 1981-03-06 1982-09-07 Sandoz Ag Fremgangsmaade til fremstilling af polypeptider
US4443434A (en) * 1982-08-18 1984-04-17 American Home Products Corporation Antiulcer agent
CH655505B (de) * 1982-08-24 1986-04-30
US4451394A (en) * 1982-10-25 1984-05-29 American Home Products Corporation Dodecapeptides preventing glucose and triglyceride assimilation
US4440904A (en) * 1983-01-31 1984-04-03 American Home Products Corporation Nonapeptide anti-secretory agents
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
JPH085913B2 (ja) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体

Also Published As

Publication number Publication date
EP0203031B1 (de) 1992-07-29
SG57793G (en) 1993-07-09
ATE78831T1 (de) 1992-08-15
IE59621B1 (en) 1994-03-09
DE3686200T2 (de) 1993-03-11
CA1333646C (en) 1994-12-20
IE861004L (en) 1986-10-25
DK174920B1 (da) 2004-02-23
EP0203031A3 (en) 1988-09-21
AU600895B2 (en) 1990-08-30
DE3686200D1 (de) 1992-09-03
AU5633886A (en) 1986-10-30
EP0203031A2 (de) 1986-11-26
DK185486D0 (da) 1986-04-22
US4725577A (en) 1988-02-16
DK185486A (da) 1986-10-26

Similar Documents

Publication Publication Date Title
EP0203031B1 (de) Biologisch wirksame Lysin enthaltende Octapeptide
US4650787A (en) Biologically active octapeptides
Spiess et al. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor
FI92210B (fi) Menetelmä farmaseuttisesti käyttökelpoisten GRF-analogien valmistamiseksi
US5084555A (en) An octapeptide bombesin analog
FI88402C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara grf-analoger
US6307017B1 (en) Octapeptide bombesin analogs
FI83660B (fi) Foerfarande foer framstaellning bukspottskoertelns grf hos maenniskan.
AU635769B2 (en) Growth hormone-releasing factor analogs
CA2097192C (en) Bombesin antagonists
US20030104981A1 (en) Human insulin analogues
JPH0133118B2 (de)
EP0017746B1 (de) Peptide mit Somatostatin-Wirkung, sie enthaltende Zusammensetzungen und Verfahren zur Herstellung der Peptide
KR100629013B1 (ko) Ｉｇｆ-ⅰ 및 -ⅱ를 억제하는 ｇｈ-ｒｈ의 길항 유사체
HU199508B (en) Process for producing grf analogues and pharmaceutical compositions comprising same as active ingredient
EP0002264A1 (de) Mit Somatostatin verwandte Verbindungen, Verfahren zu deren Herstellung und deren pharmazeutische Zusammensetzungen
EP0002262B1 (de) Mit Somatostatin verwandte Verbindungen und Verfahren zu deren Herstellung
KR900006711B1 (ko) 펩티드의 제조방법
Böhlen et al. Human growth hormone releasing factor and somatostatin from two pancreatic tumors: isolation and characterization
CA2227980A1 (en) Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone
HK1036461B (en) Antagonistic analogs of gh-rh inhibiting igf-i and -ii

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060414